Search Result

Results for "

type I TGF-β receptor kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TGF-β Receptor (9) Organoid (3)
By Research Areas:	Cancer (8) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Targets Recommended: TGF-β Receptor TGF-beta/Smad Scavenger Receptor Class B type I (SR-BI） PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13226

Galunisertib 40+ Cited Publications LY2157299	TGF-β Receptor	Cancer
Galunisertib (LY2157299) is an oral and selective **TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀** of 56 nM.

HY-78349

A 77-01 1 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily *activin-like kinase* ALK5 with an IC₅₀** of 25 nM .

HY-13012

RepSox 15+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-10432

A 83-01 Maximum Cited Publications 48 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-10432A

A 83-01 sodium Maximum Cited Publications 48 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of **TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-W684904

LY550410	TGF-β Receptor	Cancer
LY550410 is a small-molecule ATP-competitive inhibitor against **type I TGF-β receptor kinase*, which contains heteroaryl rings for potent binding to the kinase-domain active site. LY550410 modulates TGF-β* signalling, thereby regulates gene expression and ultimately cell growth. LY550410 is promising for research of cancers .

HY-13226A

Galunisertib monohydrate	TGF-β Receptor	Cancer
Galunisertib monohydrate is an oral and selective **TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀** of 56 nM.

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-114192

TGFβRI-IN-1	TGF-β Receptor	Cancer
TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC₅₀ values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library	249 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 249 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

TGF-beta/Smad Compound Library

249 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 249 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.